Literature DB >> 21869717

Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.

Benjamin M Robinson1, Catherine Kennedy, Jocelyn McLean, Brian C McCaughan.   

Abstract

INTRODUCTION: This study aimed to evaluate prognostic factors in patients with node-negative non-small cell lung cancer and to assess revised International Association for the Study of Lung Cancer staging recommendations for this group.
METHODS: A retrospective analysis of 1765 consecutive pathologically node-negative patients treated by surgical resection between 1984 and 2007 was performed. Survival analysis was conducted using the Kaplan-Meier method. The independence of prognostic factors was analyzed using multivariate Cox proportional hazards modeling.
RESULTS: The median age of patients was 68 years, and the average length of follow-up was 6.3 years. Perioperative mortality was 1.7%. The median survival was 6.5 years, with a 56% of the cohort surviving 5 years. Factors associated with poorer prognosis were male gender (hazard ratio [HR]: 1.30, p = <0.001), age (HR: 1.04 per year of increase, p < 0.001), limited resection (HR: 1.30, p = 0.002) tumor size (HR: 1.10 per 10 mm increase, p < 0.001), large cell histopathological cell type (HR: 1.35, p < 0.001), and positive resection margins (HR: 1.58, p = 0.002). T stage was a superior predictor of survival than tumor size (p < 0.001). There was no difference in survival by T-stage descriptor within stage T2 or T3.
CONCLUSIONS: In surgically treated, node-negative non-small cell lung cancer, revised International Association for the Study of Lung Cancer staging criteria stratify survival well. Age, gender, and extent of resection are also important predictors of survival. Current T-stage descriptor groupings are appropriate.

Entities:  

Mesh:

Year:  2011        PMID: 21869717     DOI: 10.1097/JTO.0b013e31822647fd

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  3 in total

1.  Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection.

Authors:  Rajwanth R Veluswamy; Grace Mhango; Marcelo Bonomi; Alfred I Neugut; Dawn L Hershman; Melissa D Aldridge; Juan P Wisnivesky
Journal:  Ann Am Thorac Soc       Date:  2013-12

2.  Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs.

Authors:  Bernardo H L Goulart; Scott D Ramsey
Journal:  Oncologist       Date:  2013-07-19

3.  Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets.

Authors:  Jun Yao; Qi Zhao; Ying Yuan; Li Zhang; Xiaoming Liu; W K Alfred Yung; John N Weinstein
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.